Previous 10 | Next 10 |
Designation is for 2 nd or 3 rd line treatment of patients with disease progression following treatment with endocrine therapy and a CDK 4/6 inhibitor Data updates and further development plans to be presented at 2023 San Antonio Breast Cancer Symposium (SABCS) ...
2023-11-16 14:12:36 ET Have you ever thought about diving into penny stocks ? These are the stocks that won’t break the bank, typically trading for less than $5. They’re a bit like roller coasters – full of ups and downs. But guess what? There’s a way to ride...
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a poster presentation of new clinical data fr...
2023-11-13 17:31:55 ET More on eFFECTOR Therapeutics HC Wainwright starts eFFECTOR at buy, cites drug technology platform For further details see: eFFECTOR Therapeutics GAAP EPS of -$0.13 misses by $0.01
Management intends to provide an update on its zotatifin clinical development program in estrogen receptor-positive (ER+) metastatic breast cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium (SABCS) Topline results from Phase 2b KICKSTART trial in non-small cell lung cancer (N...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will partici...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...
eFFECTOR Therapeutics Inc. (EFTR) is expected to report $-0.13 for Q3 2023
2023-10-24 09:02:45 ET Whether you’re trading penny stocks or stocks over $100, the goal is the same. You want to find opportunities as early as possible and capitalize. In the stock market today, there are plenty of factors affecting the way investors approach both long-term and...
News, Short Squeeze, Breakout and More Instantly...
eFFECTOR Therapeutics Inc. Company Name:
EFTR Stock Symbol:
NASDAQ Market:
eFFECTOR Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 38.2% to $0.24 on volume of 498,894,705 shares Qualigen Therapeutics Inc. (QLGN) rose 59.5% to $0.28 on volume of 243,116,946 shares NVIDIA Corporation (NVDA) fell 1.9% to $125.83 on volume o...
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 109.0% to $0.3668 on volume of 102,385,159 shares Maxeon Solar Technologies Ltd. (MAXN) rose 4.3% to $0.181 on volume of 66,422,365 shares NVIDIA Corporation (NVDA) fell 1.3% to $126.58 on volume...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 4.6% to $128.28 on volume of 215,349,874 shares Zoomcar Holdings Inc. (ZCAR) rose 34.0% to $0.183 on volume of 204,010,215 shares Maxeon Solar Technologies Ltd. (MAXN) fell 3.5% to $0.1736 on volume of 2...